Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Titel:
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Auteur:
Moreno, Carol Greil, Richard Demirkan, Fatih Tedeschi, Alessandra Anz, Bertrand Larratt, Loree Simkovic, Martin Samoilova, Olga Novak, Jan Ben-Yehuda, Dina Strugov, Vladimir Gill, Devinder Gribben, John G Hsu, Emily Lih, Chih-Jian Zhou, Cathy Clow, Fong James, Danelle F Styles, Lori Flinn, Ian W